There is no conflict of interest of any anthors in relation to this submission.
Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing–remitting multiple sclerosis
Article first published online: 23 JUN 2009
© 2009 British Society for Immunology
Clinical & Experimental Immunology
Volume 158, Issue 1, pages 26–30, October 2009
How to Cite
Xu, L., Xu, Z. and Xu, M. (2009), Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing–remitting multiple sclerosis. Clinical & Experimental Immunology, 158: 26–30. doi: 10.1111/j.1365-2249.2009.03987.x
- Issue published online: 2 SEP 2009
- Article first published online: 23 JUN 2009
- Accepted for publication 11 June 2009
- multiple sclerosis;
- regulatory T cells
Patients relapsing from multiple sclerosis (MS) are treated with high-dose, short-term intravenous injection of glucocorticoid (GC), although its mechanism of action remains only partly understood. We evaluated the ex vivo and in vitro effects of GC on regulatory T cell (Treg) function in 14 relapsing–remitting MS (RR-MS) patients in acute phase and 20 healthy controls (HC). Treg function was enhanced significantly after 5 days of GC treatment. Furthermore, there was a trend towards increasing proportions of CD4+CD25+forkhead box P3+ T cells and interleukin-10 secretion with GC treatment when compared with HC. In conclusion, GC treatment restores the impaired Treg function in patients with RR-MS in its acute phase.